Glenmark Readies New Diabetes Combo In India
Pricing Key In Crowded Sector?
Executive Summary
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.
You may also be interested in...
Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming
After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.
Battleground GLP-1s: After Chinese Firms, Glenmark Debuts Liraglutide; More Coming
After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.
Ichnos Capital Raise Key For Glenmark, BEAT Platform A Core Value Driver
All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.